Journey with AxxessBio:
Stay informed with our latest news, press releases and shared milestones

TEPADINA® (thiotepa) for Haematopoietic Stem Cell Transplantation is now approved in Malaysia

AxxessBio is pleased to announce that TEPADINA® (thiotepa) 15mg, TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 400mg multi chamber bag have been approved in Malaysia with the following indications:

TEPADINA® is indicated, in combination with other chemotherapy medicinal products:

– With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients

– When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.

*Please refer to the local package insert for full prescribing information.

Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia